“…The most frequent tumor type in study was colorectal cancer analyzed in eight studies [15] , [21] , [28] – [33] , followed by seven studies that evaluated methylation level in gastric cancer [23] , [27] , [32] , [34] – [37] , five in hepatocellular carcinoma [25] , [38] – [41] , four in bladder cancer [1] , [14] , [42] , [43] and head and neck carcinoma [10] , [44] – [46] , two in lung cancer [47] , [48] and breast cancer [24] , [49] , and single studies assessed methylation levels in renal cell cancer [50] , prostate cancer [51] , neuroendocrine tumor [52] , ovarian cancer [53] , thyroid cancer [54] , esophageal cancer [26] , cervix cancer [55] , endometrial cancer [32] , skin melanoma [22] , testicular cancer [56] , leukemia [57] , multiple myeloma [58] , paraganglioma [59] , fibrolamellar carcinoma [60] and gastrointestinal [61] . Four studies evaluated methylation level in several cancer sites [13] , [28] , [29] , [32] .…”